Antiparasitic Drugs Market (By Drug Type: Anthelmintic, Antiprotozoal; By Route of Administration: Oral, Injectable, Topical; By Distribution Channel: Hospital pharmacies, Retail pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global antiparasitic drugs market size surpassed USD 18.50 billion in 2023 and is projected to hit around USD 30.42 billion by 2033, growing at a CAGR of 5.10% from 2024 to 2033.
The increasing cases of parasite infections such as malaria, toxoplasmosis, etc002E, by the environment, impaired quality of water, bug bites, etc., are driving the growth of the antiparasitic drugs market.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. antiparasitic drugs market size was valued at USD 4.79 billion in 2023 and is anticipated to reach around USD 7.88 billion by 2033, poised to grow at a CAGR of 5.12% from 2024 to 2033.
North America dominated the antiparasitic drugs market with the largest market share of 37% in 2023. The growth of the market is owing to the rising awareness about health among the people, and the rising healthcare infrastructure is boosting the growth of the market. The increasing investments in the development of healthcare infrastructure and the well-established pharmaceutical industry are accelerating the growth of the antiparasitic drugs market. The increasing R&D and the launch of innovative videos are driving the demand for the market.
Asia Pacific is expected to witness significant growth in the antiparasitic drugs market during the forecast period. The growth of the market is owing to the developing healthcare infrastructure and the pharmaceutical industries in countries like China, India, and Japan, which are boosting the growth of the market. The ongoing technological development in the pharmaceutical industry and the launch of innovative medicines are boosting the growth of the antiparasitic drugs market in the region.
The antiparasitic drugs market offers therapeutics that are prescribed to treat infections caused by parasites. The microscopic creatures known as parasites, which reside on or inside humans and animals, cause many illnesses. Antiparasitic medications come in a wide variety. Every medicine specifically targets a parasite. The illnesses they treat can have mild to severe symptoms. Throughout the world, parasites are the source of billions of infections. Parasitic infections come in a variety of forms. Malaria is among the most widespread parasite illnesses. Periodically, gastroenteritis (stomach flu) can be brought on by parasites.
The global expansion of parasitic illnesses has been attributed to greater migration and international travel. The antiparasitic medicine industry is expected to benefit from expanding R&D activity as well as an increase in company collaborations aimed at the growth of the market during the forecast period.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 5.10% |
Global Market Size in 2023 | USD 18.50 Billion |
Global Market Size by 2033 | USD 30.42 Billion |
U.S. Market Size in 2023 | USD 4.79 Billion |
U.S. Market Size by 2033 | USD 7.88 Billion |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Drug Type, By Route of Administration, and By Distribution Channel |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Increasing parasitic infection
The ongoing spread of parasitic infections due to viral disease transmission, environment, contaminated food, bug bites, water, eating undercooked food, etc., has caused a substantial demand for therapeutic solutions. The parasite infection causes fatigue, fever, skin rashes, itchiness, intestinal symptoms, and neurological symptoms. Malaria, toxoplasmosis, head ice, giardiasis, and pinworms are the most common parasite infections that can be found in the human body. Each parasite infection has a different kind of treatment and dosage. Antiparasitic drugs work by limiting the growth of parasites and killing parasites or their eggs. Thus, the rising environmental changes, eating habits, and other reasons for the spread of infections are driving the demand for the antiparasitic drugs market.
Restraint: Regulatory policies and side effects associated with drug use
Regulatory policies exercise restrictive control on the antiparasitic drugs market. They influence several aspects of the drug development process. The rigid approval process mandated by regulatory bodies retard the product development and manufacturing process dockets while simultaneously adding to the retail prices, generating intimidating barricades to market entry. Another aspect of market retardation is a lack of awareness of antiparasitic drugs in rural and underdeveloped economies, and the side effects of the drugs, in some cases, are limiting the growth of the antiparasitic drugs market.
Opportunity: Increasing research and development
The rising investments by the government, research centers, pharmaceutical firms, and private investors in the research and development program for the development of antiparasitic drugs are driving the opportunity for the growth of the market. Increasing collaboration with the major market firms for the development of the medical drugs market is anticipated to drive the growth of the antiparasitic drugs market.
The anthelmintic drug segment dominated the antiparasitic drugs market in 2023. The growth of the segment is attributed to the rising infection of the helminthic in low and medium-income countries, boosting the demand for the segment in the anthelmintic drug market. The helminths are divided into three groups- cestodes, nematodes, and trematodes, which are also known as tapeworms, roundworms, and flukes respectively. Helmintics differ from infectious organisms. There are various drugs used for the treatment of worm infections. Most of the drugs are administered orally and used in both human and veterinary medicines. The increasing cases of helminth in low- and middle-income countries are driving the demand for anthelmintic drugs in the market.
The antiprotozoal drug segment is expected to grow at the fastest rate in the market during the forecast period. The rising cases of protozoal infection and diseases like malaria, toxoplasmosis, and leishmaniasis drive the demand for the segment in the market. Antiprotozoal drugs are strictly prescription medicines and can be available in various forms of dosage like capsules and tablets, and also available in the forms of powder for prepared as an injectable solution.
The injectable segment projected higher growth in the market in 2023. The growth of the segment is attributed to the higher efficiency of drugs due to the administration of drugs via injections, which is driving the growth of the segment in the market. Injectable administration directly allows the drug to be delivered to the bloodstream and shows the rapid results of the drug. Injectable administration is a direct fight against the infection-causing bacteria in the body due to its direct administration of drugs into the bloodstream. Thus, all these factors are driving the growth of the segment in the market.
The topical segment is expected to grow in the market during the anticipated period. The topical administration of drugs means the medicines are directly applied to the infected skin or hair. Most of the parasites are impacted by the infection on the skin, causing rashes and itchiness. Thus, topical administration is given relief in such kinds of conditions. All these factors are boosting the growth of the segment in the antiparasitic drugs market.
The hospital pharmacies segment dominated the antiparasitic drugs market in 2023. The growth of the segment is attributed to the rising availability of medical professionals, infrastructure, and the handling of injectables administered antiparasitic, which is effectively driving the growth of the segment in the market. Hospital pharmacies, having medical expertise and a higher availability of drugs and hospital staff to look after the patients, accelerate the growth of the hospital pharmacies segment.
The retail pharmacies segment is expected to grow at the fastest pace during the predicted period. The growth of the segment has increased due to the rising cases of first aid drugs or medicines for treatment by the nearby retail pharmacies, which is boosting the demand for the antiparasitic drugs market in the retail pharmacies.
Segments Covered in the Report
By Drug Type
By Route of Administration
By Distribution Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antiparasitic Drug Market
5.1. COVID-19 Landscape: Antiparasitic Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antiparasitic Drug Market, By Drug Type
8.1. Antiparasitic Drug Market Revenue and Volume, by Drug Type, 2024-2033
8.1.1 Anthelmintic
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Antiprotozoal
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Antiparasitic Drug Market, By Route of Administration
9.1. Antiparasitic Drug Market Revenue and Volume, by Route of Administration, 2024-2033
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Topical
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Antiparasitic Drug Market, By Distribution Channel
10.1. Antiparasitic Drug Market Revenue and Volume, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Antiparasitic Drug Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
Chapter 12. Company Profiles
12.1. GlaxoSmithKline plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck KGaA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client